Lv1
30 积分 2023-02-19 加入
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial
6天前
已完结
The Relationships between HER2 Overexpression and DCIS Characteristics
10天前
已完结
Comparison of Radiation With or Without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy: A Phase III Clinical Trial
11天前
已完结
Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
13天前
已完结
Comparison of Radiation With or Without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy: A Phase III Clinical Trial
15天前
已完结
BRCA1-Mediated Dual Regulation of Ferroptosis Exposes a Vulnerability to GPX4 and PARP Co-Inhibition in BRCA1-Deficient Cancers
1个月前
已完结
SLC25A1 and ACLY maintain cytosolic acetyl-CoA and regulate ferroptosis susceptibility via FSP1 acetylation
1个月前
已关闭
Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade
2个月前
已完结
Ductal carcinoma in situ of the breast: finding the balance between overtreatment and undertreatment
2个月前
已完结
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
4个月前
已完结
皖公网安备34019202002308
